Robert

Robert K. Schultz, PhD
Founder President and Chief Executive Officer

Dr. Schultz has more than 35 years of experience in pharmaceutical and medical device development. He is the President and CEO of Sollievo Pharmaceuticals, Inc.

Dr. Schultz previously served as President and Chief Operating Officer of REVA Medical, Inc., a San Diego-based medical device company. From 2003 to 2017 he was responsible for converting in- licensed drugs and polymers into fully biodegradable, radiopaque cardiovascular stents and drug delivery products. REVA’s first commercialized product, Fantom®, using proprietary and highly unique technology, gained CE Mark approval in 2017. Dr. Schultz built and led a dynamic team of scientists, engineers, operations, and administrative professionals. During his tenure, REVA raised $250 million from a range of sources, including a successful IPO listing in Australia in 2010.

Prior to REVA, Dr. Schultz held executive and research positions at Dura Pharmaceuticals and 3M Pharmaceuticals, where he spearheaded development and commercialization of dry powder and non-CFC inhalers.

Dr. Schultz’s expertise includes technical, business development, and executive leadership in the areas of conventional drug products, aerosol delivery, drug development, and cardiovascular devices. His expertise in early stage technology development has led to a passionate ability to accelerate progress on limited time and budgets.

Dr. Schultz received his BS in Pharmacy and PhD. in pharmaceutics from the University of Minnesota.

Katrina

Katrina L. Thompson
Chief Financial Officer

Ms. Katrina L. Thompson has over 35 years of experience in finance, accounting, and corporate administration. She is providing financial and administrative services to Sollievo Pharmaceuticals, Inc.

Ms. Thompson previously served as Chief Financial Officer and Corporate Secretary of REVA Medical, Inc. from 2003 to 2017. She led the financial and administrative functions of REVA during the development and commercialization of the company’s bioresorbable coronary stent products. During her tenure, REVA raised $250 million, including a successful IPO listing in Australia in 2010 and two follow-on financings that provided funding for final development and initial commercialization activities.

Prior to REVA, Ms. Thompson held management and executive positions at a variety of public and private companies, including commercial real estate, high technology, and agricultural industries. She obtained her CPA certificate while working at Price Waterhouse in audit services.

Ms. Thompson received her BS in accounting from San Diego State University.

Sollievo Pharmaceuticals, Inc

To get more information about our product or any other questions

Get In Touch